0000874716-23-000117.txt : 20230905
0000874716-23-000117.hdr.sgml : 20230905
20230905170120
ACCESSION NUMBER: 0000874716-23-000117
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230831
FILED AS OF DATE: 20230905
DATE AS OF CHANGE: 20230905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MAZELSKY JONATHAN JAY
CENTRAL INDEX KEY: 0001556270
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19271
FILM NUMBER: 231236691
MAIL ADDRESS:
STREET 1: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092
FORMER NAME:
FORMER CONFORMED NAME: MAZELSKY JAY
DATE OF NAME CHANGE: 20120815
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDEXX LABORATORIES INC /DE
CENTRAL INDEX KEY: 0000874716
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 010393723
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092-2041
BUSINESS PHONE: 2075560300
MAIL ADDRESS:
STREET 1: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092-2041
FORMER COMPANY:
FORMER CONFORMED NAME: IDEXX CORP / DE
DATE OF NAME CHANGE: 19600201
4
1
wk-form4_1693947669.xml
FORM 4
X0508
4
2023-08-31
0
0000874716
IDEXX LABORATORIES INC /DE
IDXX
0001556270
MAZELSKY JONATHAN JAY
ONE IDEXX DRIVE
WESTBROOK
ME
04092
1
1
0
0
President and CEO
0
Common Stock
2023-08-31
4
M
0
13424
79.54
A
86349.3456
D
Common Stock
2023-08-31
4
S
0
13424
512.0133
D
72925.3456
D
Non-Qualified Stock Option (right-to-buy)
79.54
2023-08-31
4
M
0
13424
D
2025-02-13
Common Stock
13424
13424
D
Represents the weighted average price of the shares sold ranging from a low of $512.00 to a high of $512.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Grant of option to buy 13,424 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
Not applicable.
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky
2023-09-05